As biosims win nods in Europe and India, debate over naming rights …
From www.fiercepharma.com – January 29, 2014
What’s in a name? In the pharmaceutical world, the answer to this question is no simple matter. Drugmakers, biotechs and their generic rivals are squabbling over the names that will be assigned to biosimilars, in a battle for a marketing edge.
Should biosimilars have the same International Proprietary Names or unique, non-proprietary, or generic names to distinguish the medicines from the original biologics?
Read more: As biosims win nods in Europe and India, debate over naming rights heats up – FiercePharma http://www.fiercepharma.com